Aberdeen Group
NVO

Aberdeen Group’s Novo Nordisk NVO Stock Holding History

Aberdeen Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7M Sell
481,520
-133,346
-22% -$6.32M 0.03% 458
2025
Q4 		$31.3M Buy
614,866
+429,351
+231% +$22M 0.05% 312
2025
Q3 		$10.3M Sell
185,515
-70,525
-28% -$4.13M 0.02% 601
2025
Q2 		$17.7M Sell
256,040
-24,694
-9% -$1.68M 0.03% 448
2025
Q1 		$19.5M Buy
280,734
+20,565
+8% +$1.7M 0.04% 394
2024
Q4 		$22.3M Buy
260,169
+27,784
+12% +$3M 0.04% 346
2024
Q3 		$27.7M Sell
232,385
-8,999
-4% -$1.2M 0.05% 317
2024
Q2 		$34.5M Buy
241,384
+73
+0% +$9.67K 0.07% 271
2024
Q1 		$31M Buy
241,311
+13,679
+6% +$1.63M 0.06% 295
2023
Q4 		$23.5M Buy
+227,632
New +$22.5M 0.05% 349

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Aberdeen Group's NVO Position: Q1 2026 in Review

Aberdeen Group reduced its Novo Nordisk (NVO) stake by 22% in Q1 2026, selling an estimated $6.32M and leaving 481,520 shares worth $17.7M. The position accounts for 0.03% of the portfolio, ranked #458.

Aberdeen Group first reported a position in NVO in Q4 2023 and has held it in 10 quarters since. The position peaked at $34.5M in Q2 2024. 1,270 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Aberdeen Group held 481,520 shares of Novo Nordisk worth $17.7M as of Q1 2026.
  • Aberdeen Group sold 133,346 Novo Nordisk shares in Q1 2026, an estimated $6.32M.
  • Novo Nordisk made up 0.03% of Aberdeen Group's portfolio in Q1 2026, its #458 holding.
  • Aberdeen Group first reported a position in Novo Nordisk in Q4 2023 and has held it in 10 quarters since.
  • Aberdeen Group's Novo Nordisk position peaked at $34.5M in Q2 2024.
  • 1,270 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.